Creating a resource for studying pituitary neuroendocrine tumors
Official title: The National Biorepository and Resource for Pituitary Neuroendocrine Tumor Translational Research (BioPitNeT)
Funded at University of Georgia · NIH-11249449 · Data updated 2026-11-12
This study is looking at hormone-secreting tumors in the pituitary gland, especially Cushing’s disease, to better understand them and find new treatments that could help patients feel better and manage their condition more effectively.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Georgia NIH-funded |
| Lab location | 1 site (Athens, United States) |
| Project start | December 19, 2024 |
| Project end | July 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $2,819,349 |
| NIH project number | 7RC2DK140838-02 |
| Project ID | NIH-11249449 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with pituitary neuroendocrine tumors, particularly those suffering from Cushing’s disease.
✕Less likely to help
Patients with other types of tumors or those not diagnosed with pituitary neuroendocrine tumors may not receive any benefit from this research.
What this research studies
This research focuses on pituitary neuroendocrine tumors (PitNETs), particularly Cushing’s disease, which is caused by hormone-secreting tumors that lead to serious health issues. The project aims to establish a biorepository and deep tumor phenotyping platform to enhance understanding of these tumors and develop targeted therapies. By collecting and analyzing tumor samples, the research seeks to uncover the cellular and molecular complexities of PitNETs, ultimately improving treatment options and patient outcomes. Patients may benefit from improved therapies and better management of their condition as a result of this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with pituitary neuroendocrine tumors, improving their quality of life and survival rates.
How similar studies have gone: While research on pituitary neuroendocrine tumors is limited, the establishment of biorepositories and deep phenotyping platforms has shown promise in other cancer research areas.
Where this research is happening
-
University of Georgia
Athens, United States Active
Researchers
- Principal investigator: Zavros, Yana — University of Georgia
- Study coordinator: Zavros, Yana
Related research
Other NIH-funded projects on the same topics.
-
BRD4 and NIPBL work together to control facial bone development
A study in mice and cell models will explore how BRD4 and NIPBL work together to control how genes are turned on in facial development, which could clarify causes of craniofacial disorders.
-
Sulfated glycosaminoglycan hydrogels to protect brain volume after traumatic injury
A new implantable gel made from specially sulfated sugars may help prevent brain shrinkage and improve function after a serious brain injury.
-
Understanding how Kaposi’s sarcoma virus switches on late genes during infection
Scientists are studying how the virus causing Kaposi’s sarcoma turns on late genes when its DNA copies itself, which could reveal new ways to treat cancer in people with AIDS.
-
Understanding how cells control signals and adhesion with the secretory pathway
A funded NIH project looks at how the cell’s secretory system shapes signals, receptors, and attachment to the outside of the cell, which can influence many human diseases.
-
AI-powered math and machine learning for bioscience and drug discovery
A broad NIH grant supports using advanced math and AI to better predict viral variants and aid drug discovery, with the goal of helping patients by accelerating pandemic response.
-
AI-driven platform to predict vaccine-escape variants and design mutation-proof antibodies
An AI-powered approach aims to anticipate SARS-CoV-2 variants that may dodge vaccines and to create antibodies that stay effective.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.